In Silico Studies of Drug Discovery and Design Against COVID-19 Focusing on ACE2 and Spike Protein Virus Receptors: A Systematic Review
by Matheus prayoga claus ★ , Masteria Yunovilsa Putra, Arry Yanuar ★
Academic editor: Ernest Domanaanmwi Ganaa
Sciences of Pharmacy 2(3): 73-78 (2023); https://doi.org/10.58920/sciphar02030073
This article is licensed under the Creative Commons Attribution (CC BY) 4.0 International License.
11 May 2023
07 Jun 2023
13 Jun 2023
06 Jul 2023
Abstract: The emergence of COVID-19 has prompted researchers worldwide to focus on developing drugs that specifically target ACE2 receptors and SARS-CoV-2 Spike Protein receptors. They have embraced an in-silico approach that employs virtual screening, molecular docking, and molecular dynamics to achieve this. This innovative method harnesses existing chemical and natural product databases to identify the most suitable ACE2 receptor blockers and SARS-CoV-2 Spike Protein inhibitors. By following the PRISMA statement guidelines, a thorough literature search yielded 21 relevant articles, forming the basis of this systematic review. The review provides a comprehensive summary and detailed description of the methodologies, protocols, software tools, and noteworthy drug candidates identified in these studies. Additionally, it sheds light on the crucial molecular interactions by presenting an overview of the interacting residues elucidated in the reviewed articles, offering valuable insights for effective therapeutic interventions. Furthermore, the review presents thought-provoking suggestions for future research directions, aiming to inspire and guide advancements in drug development efforts.
Keywords: Drug discoveryACE2Spike Protein Virusmolecular docking
1. Introduction
Coronaviruses are enveloped RNA viruses that are widely
distributed among humans and other animals and can cause respiratory, enteric,
and hepatic diseases in most cases (1).
Severe Acute Respiratory Syndrome – Corona Virus (SARS-CoV)
was the primary cause of severe acute respiratory syndrome outbreaks in Guangdong
Province, China, in 2002 and 2003. In 2004, several reports from laboratory and
nonlaboratory cases highlighted the possibility of SARS re-emergence (2).
In late December 2019, there was a report about emerging pathogens linked to
coronaviruses. Local health facilities in Wuhan reported several clusters of
patients with pneumonia of unknown origin linked to a seafood and wet animal
wholesale market in Hubei Province, China (3).
Previous research in viral diagnostics, isolation and identification has
revealed that the novel virus shares more than 85% identity with a bat
SARS-like CoV genome. Further analysis of the 2019-nCoV genome from clinical
specimens reveals 86.9% nucleotide sequence identity to a previously published
bat SARS-like CoV. Although it is similar to some beta coronaviruses found in bats,
it is not the same as SARS-CoV (4).
This study served as the foundation for many subsequent studies on novel
coronavirus drug discovery and vaccine development.
Another critical research is on the matter of viral
receptors in the human body. SARS-CoV-2 uses human Angiotensin-converting
Enzyme 2 (ACE2) as an entry receptor with similar affinity to previous
SARS-CoV isolates, according to Walls et al. (5), indicating that the
virus could spread effectively in humans. Another study by Zhou et al. (6) found that SARS-CoV-2
can use all ACE2 proteins, except mouse ACE2, as an entry point to enter cells
that express ACE2, but not those that do not, indicating that ACE2 is the cell
receptor through which the virus can enter the cells. They also show that
SARS-CoV-2 does not use previous SARS-CoV receptors such as aminopeptidase N
(APN) and dipeptidyl peptidase 4 (DPP4).
Drug discovery and development is a complicated process that
needs extensive research and also has high-risk factors of failure (7). Conventional drug
discovery methods could take more than a decade to complete, and the cost of
research could be prohibitively expensive, which could
reach around $70 mil- lion for each NME reaching the clinic (8). The failure that could
occur in the process namely lack of clinical efficacy, unmanageable toxicity, poor
drug-like properties and lack of commercial needs (9). Computational methods
such as virtual screening and molecular docking could assist in the early
stages of discovery (10). Modern
computational-aided drug design is divided into two parts based on the
molecular information source utilized, which are structure-based drug design
and ligand-based drug design (11). Compounds from the
existing database or new chemical entities could be screened more quickly to
find the hit and lead compound, which could then be developed further to become
the final drug (12).
In this article, the authors conducted a systematic review
of drug discovery research and methods by using computational methods to find
drug candidates from drug repurposing or a database of chemical entities. The
authors systematically selected documentation on this subject and compared
different computational analysis methods towards the ACE2 receptor or Spike
Protein SARS-CoV-2 receptor in the current study.
2. Materials and Methods
2.1 Study Protocols
The Preferred Reporting Items for Systematical Reviews and
Meta-Analysis (PRISMA) statement is used as a guideline to conduct the
literature search (13). For the search
strategy, the following descriptors were employed: “ACE2”, “SARS-CoV-2”, “Spike
Protein”, “in silico”, “computational”, “virtual screening”, and
“molecular docking” using the Boolean operator. The search was conducted in
ScienceDirect. The potential studies were screened according to the inclusion
and exclusion criteria.
2.2 Inclusion and Exclusion Criteria
The inclusion criteria for this article review were: (1)
experimental studies written in English, (2) studies that use virtual screening
or molecular docking as their drug discovery method, (3) databased used in the
studies are existing drug databases or databases of natural product with
non-peptide small molecule and (4) studies are published in the range year 2020
- 2023.
The exclusion criteria were: (1) studies written in other
languages besides English, (2) non-related studies such as: (a) in vitro
studies using cell line, (b) synthesis method, (c) computational using
artificial intelligence, (d) network analysis method, (e) screening or docking
using modified structure, (3) duplicate publications, (4) articles not
available as full text.
2.3 Selection of Studies and Data Collection
All search results were collected and screened. All
identified studies are assessed based on the title and abstract without using
any specific data extraction form. The data are gathered according to the year
of publication, computational method, and database used in the study.
2.4 Quality of Article Assessment Study
The idea of bias in computational drug research studies is
not well established, therefore it is hard to determine the risk of bias in
this type of study. The authors decided to go with a tool designed for the
assessment in a similar in silico review published by Mohamed et al. (14) with some refinement.
The assessment encompassed five main aspects of the quality of studies included
in the present systematic review: design (single-target or bi-target or
multi-target), target template and crystal resolution, docking tools, molecular
dynamics simulation (yes or no) and the resource of the database. The quality of
each eligible article was appraised by the author.
3. Results and Discussion
3.1 Literature Collection Process
The keywords used in the literature search yielded 790 research articles published between 2020 and 2023. Only 76 of those articles met the criteria for related studies. We retrieved 52 potential literature articles from the 76 articles and excluded 24 articles because they were written in a language other than English, the method used was unclear, or it was a review article that was missed in the first screening. We evaluated the retrieved articles for eligibility and decided to exclude 31 records that used a modified structure for docking, an in vitro method, a synthesis method, AI simulation, and network analysis. As a result, 21 articles were identified as meeting the inclusion criteria and were given full consideration. The final 21 articles are processed to the Quality of Article Assessment Study.
[Figure 1]
Figure 1. PRISMA flowchart for the literature search process.
3.2 Quality of Article
Assessment Study and Summary of Studies
We have summarized the quality of articles in our studies in
Table 1. Bias in computational drug research studies is not well established,
as stated in the methods. But one potential bias is the target's molecular
plasticity. The target's flexibility is usually limited or ignored when only
molecular docking is used in a study. In this case, MD simulation could play a
key role in drug discovery and design, as well as pre-and post-docking
simulation. It can be used as a generator for multiple target conformations for
virtual screening, or as a validator for post-docking to distinguish between
improper docking poses and meaningful ones (15). 13 of our reviewed
papers have been validating further by using various molecular dynamics
programmes such as GROMACS (16), UNRES (17), NAMD (18), Schrodinger Desmond (19), and AMBER (20).
Table 1. Quality of articles
included in systematic review.
No. |
First Author, Year |
Targets |
Target Template |
Crystal Resolution (Å) |
Docking Tools |
MD Simulation |
Resource of structure Database |
||||||
Sgl |
Sgl+ |
Dbl |
Dbl+ |
Spike Protein |
ACE2 |
Spike Protein |
ACE2 |
Yes |
No |
||||
1 |
Gurung, 2022 (21) |
|
|
|
|
7WBL |
|
3.40 |
|
Autodock 4.2 |
Gromacs |
|
PubChem |
2 |
Kulkarni, 2020 (22) |
|
|
|
|
6M0J |
|
2.45 |
|
Autodock Vina |
|
|
PubChem |
3 |
Rameshkumar, 2021 (23) |
|
|
|
|
6VW1 |
|
2.68 |
|
Autodock Vina |
|
|
Var. |
4 |
Natesh, 2021 (24) |
|
|
|
|
6W41 |
1R42 |
3.08 |
2.20 |
Autodock Vina |
|
|
PubChem |
5 |
Al-shuhaib, 2022 (25) |
|
|
|
|
|
1R42 |
|
2.20 |
GLIDE |
UNRES |
|
PubChem |
6 |
Hadni, 2022 (26) |
|
|
|
|
6M17 |
|
2.90 |
|
Autodock 4.2 |
NAMD |
|
PubChem |
7 |
Kar, 2022 (27) |
|
|
|
|
6M0J |
|
2.45 |
|
Autodock Vina |
Gromacs |
|
PubChem |
8 |
Vardhan, 2020 (28) |
|
|
|
|
2GHV |
6M17 |
2.20 |
2.90 |
Autodock Vina |
CABS-flex 2.0 |
|
Var. |
9 |
Kiran, 2022 (29) |
|
|
|
|
6VSB |
|
3.46 |
|
Cresset Flare Docking |
|
|
PubChem |
10 |
Jain, 2021 (30) |
|
|
|
|
6M0J |
|
2.45 |
|
Autodock Vina |
Gromacs |
|
PubChem |
11 |
Khan, 2021 (31) |
|
|
|
|
|
6M0J |
|
2.45 |
Autodock Vina |
Gromacs |
|
PubChem |
12 |
Benítez-Cardoza, 2020 (32) |
|
|
|
|
|
1R42 |
|
2.20 |
Autodock + MOE |
|
|
EXPRESS-pick |
13 |
Gowrishankar, 2021 (33) |
|
|
|
|
6VYB |
1R42 |
3.20 |
2.20 |
Autodock 4.2 |
Gromacs |
|
PubChem |
14 |
Muhseen, 2020 (34) |
|
|
|
|
6LZG |
|
2.50 |
|
Autodock Vina |
Gromacs |
|
NPACT + MPD3 |
15 |
Akinlalu, 2021 (35) |
|
|
|
|
|
6LZG |
|
2.20 |
Autodock Vina |
|
|
DrugBank |
16 |
Baby, 2021 (36) |
|
|
|
|
|
1R4L |
|
3.00 |
GLIDE |
Schrodinger Desmond |
|
DrugBank |
17 |
Pokhrel, 2021 (37) |
|
|
|
|
|
1R4L |
|
3.00 |
Autodock 4.2 |
Schrodinger Desmond |
|
Ambinter |
18 |
Yu, 2022 (38) |
|
|
|
|
7DF4 |
7DF4 |
3.80 |
3.80 |
Autodock Vina |
|
|
TCM |
19 |
Singh, 2022 (39) |
|
|
|
|
6LZG |
6M0J |
2.50 |
2.45 |
Autodock 4.2 |
Gromacs |
|
PubChem |
20 |
Mishra, 2021(40) |
|
|
|
|
6M0J |
6M0J |
2.45 |
2.45 |
GLIDE |
Schrodinger Desmond |
|
PubChem |
21 |
Nabati, 2022 (41) |
|
|
|
|
6M0J |
|
2.45 |
|
Autodock Vina |
|
|
ChemDiv |
The majority of the reviewed
articles use GROMACS and Schrodinger Desmond as their methods of validation and
use various configurations for the simulation. 9 articles used a single target
as their receptors, which is either ACE2 or the SARS-CoV-2 Spike Protein (SP),
while 6 of the articles use a single target but with addition other than ACE2
or the SARS-CoV-2 SP. One article used exactly
double targets which are ACE2 and SARS-CoV-2 SP, and the last 5 use both
targets with the addition of another target. These other targets are proteins
which also contribute to the infection or multiplication process of the virus
such as Main protease (Mpro)/3-chymotrypsin-like protease (3CLpro), papain-like
protease (PLpro), RNA-dependent RNA polymerase (RdRp), and other non-structural
protein (Nsp) for example Nsp-3 and Nsp-9. Crystal resolution is also one of
the crucial parameters in molecular docking and dynamics studies. In this review,
all the crystal structures used in the studies range from 2 Å to 4 Å,
considered adequate.
Resolution is defined as a metric for assessing the quality
of data collected on the protein or nucleic acid crystal. It evaluates the
level of detail in the diffraction pattern as well as the level of detail that
will be visible when the electron density map is computed (42). Higher resolution
values, such as 1Å, are highly ordered and allow you to see every atom in the
electron density map, whereas lower resolution values, such as 3Å or higher,
only show the basic contours of the protein chain (43,44).
The docking tools mainly used in the reviewed literature are
Autodock4 (45) and Autodock Vina (46), though other tools are
being used such as GLIDE (47), Cresset Flare (48), or MOE (49). The structure of the
database mainly comes from PubChem (50), but other databases
such as DrugBank (51), Ambinter (52), and ChemDiv (53) are also being used.
Table 2 provides a comprehensive summary of the included
studies, highlighting the methods, protocols, software, ligand candidates,
targets, grid sizes in virtual screening and molecular docking,
ADMET/physicochemical analysis software, and key interacting residues. Moreover,
the table also delineates the important residues implicated in the molecular
interactions under investigation, providing valuable insights into the specific
amino acids or functional groups involved in driving the observed effects. This
information serves as a valuable resource for understanding the research
parameters and findings. In subsequent subsections, we discuss each parameter
in detail, offering insights into the methodologies employed and their implications.
This comprehensive analysis aims to provide a deeper understanding of the
reviewed studies, shedding light on the approaches utilized and their impact on
the field of research.
3.3 Virtual Screening
There are millions of chemical 'libraries' that a trained
chemist could hope to synthesise. Combinatorial chemists have already
demonstrated in several prototype systems that libraries containing
1,000-100,000 compounds can be assembled (54). Virtual screening help
chemist decides what compound should be synthesised (55). Virtual screening can
be done by docking method or pharmacophore method.
Pharmacophores are the "refined" essence of what
makes an effective ligand-receptor interaction, explicitly three-dimensional,
and represent fundamental physicochemical aspects of ligand-receptor
interactions, and are extremely useful when experimental structural data is
unavailable and homology models are unreliable. In that case, a good
pharmacophore model could give powerful insight and screen more effectively (56,57). Since the conformer is
only compared against a three-point pharmacophore model, the method of
virtual screening using pharmacophore could be very useful for a large number
of compounds when compared to virtual screening using the docking
method (54). This is due to the
memory used for each conformation is not as large relative to when docking
is required.
This method of virtual screening using pharmacophore could
be seen in the work of Pokhrel et al. (37) which screened more
than 11 thousand from the Ambinter database. The complicated steps in the
pharmacophore model method are in the step of model validation. The literature
used the GH scoring method for pharmacophore model validation and also includes
enrichment factor and goodness of hit score. This validation needs to use a set
of other databases called decoy compounds, which are usually available in the
Database of Useful Decoys (DUDe) (58). This database has to
be compared to active compounds in this matter they use known active ACE2
inhibitors from CheMBL (59) and a literature
search. After the model is validated, then it can be used as the parameter for
the screening. This could be a problem when there is no available decoy
database, or the number of active compounds is inadequate.
Table 2. Summary of studies included in the
systematic review.
Ref. |
Method, Protocol |
Software |
Ligand |
Target |
Grid Size (Å) |
MD |
ADMET |
Candidate Drugs (ΔG) (kcal/mol) |
Std. Ref. |
Important Residue |
(21) |
PISA, MolDoc PhysProp MD |
PDBsum, ADT 1.5.6, AD4.2, DW 4.6.1, GROMACS 2019.2, LigPlot+ v1.4.5 |
36 compounds with a preclinical or clinical trial against previous
variants |
SP Omicron - hACE2 (7WBL) |
36 x 52.875 x 57.75 |
100ns 300K |
DW 4.6.1 |
Abemaciclib (-10.08), Dasatinib (-10.06), Spiperone (-9.54) |
- |
SP : Phe338, Asp339, Asp364 |
(22) |
Act.Site, MolDoc, DFT |
PyRx, ADV |
Major components of essential oils |
ACE2-RBD (6M0J) |
(adjusted according to active site residues that are selected) |
- |
- |
Anethole (-5.2), Cinnamaldehyde (-5.0), Carvacrol (-5.2), Geraniol (-5.0), Cinnamyl acetate (-5.2), L-4-terpineol (-5.1), Thymol (-5.4), Pulegone (-5.4) |
- |
SP : Arg454, Ser459, Glu471, Tyr505 |
(23) |
VS, MolDoc, PhysProp DL |
ADV, AD4.1, CoDockPP, SA |
458 flavonoid compounds |
SP Omicron - hACE2 (6VW1), Mpro (6LU7), RdRp (6M71) |
40 x 40 x 40 |
- |
SA |
Albireodelphin (-11.2), Amentoflavon (-10.2), Cupressuflavon (-10.0), Agathisflavone (-9.9) |
- |
SP: Thr319, Thr394, Phe396, Arg553, Lys621, Asn628, Asp760, Asp761 |
(24) |
MolDoc, ADMET |
ADT ADV, ADMETLab, PT2, OSIRIS Property |
Standard drugs and spices |
Spike Protein (6W41), ACE2 (1R42), Mpro (6LU7) |
(Interacting critical residues in Spike Protein and ACE2 complex) |
- |
AL, PT2, OSIRIS |
Bioactives in asafoetida and sesame seed |
Remdesivir |
ACE2 : His34, Glu37, Asp38, Arg393 SP : Arg403, Gln493, Ser494 |
(25) |
MolDoc, ADMET, MD |
GLIDE, SA, UNRES online server |
3392 compounds from Iraqi medicinal plants |
ACE2 (1R42) |
30 x 30 x 30 |
250ns 300K |
SA |
Epicatechin (-6.05) |
- |
ACE2 : Asp30, Asn33, His34, Glu37 |
(26) |
MolDoc, ADMET, MD |
ADT, AD4.2, DSV. |
Bioactive flavonoids compounds |
Spike Protein RBD (6M17), 3CLpro (6LU7) |
60 x 60 x 60 |
100ns 310K |
ADMET parameters |
Herbacetin (-8,03), Morin (-8,46), Silibinin (-9,03), Tomentin E (-8.32), Amentoflavone (-10.19), Bilobetin (-8,89), Baicalein (-8.19), Quercetin (-8.26) |
- |
SP: Glu35, Asp38, Lys353, Glu406, Try453, Ser494, Gly496, Asn501, Tyr505 |
(27) |
MolDoc, ADMET, MD, PCA |
ADV, ADT, SA pkCSM, LigPlot+. PLIP. GROMACS 2018.3 |
300 compounds from 25 Indian medicinal plants |
ACE2-RBD (6M0J), Mpro (6LU7) |
50 x 50 x 50 |
100ns 300K |
SA, pkCSM |
Oleanderolide (-8.3), Proceragenin A (-8.3), Balsaminone A (-8.3) |
- |
SP : Cys336, Gly339, Asn343, Ala348, Arg355. Ser373, Asp428, Thr430
Phe515, |
(28) |
MolDoc, MD, ADMET, PLI |
ADV, pkCSM, Mi, CABS-flex 2.0 online, |
154 phytochemicals in Limonoids and Triterpenoids class |
SP (2GHV), ACE2 (6M17), 3CLpro (6LU7), Plpro (4MM3), RdRp (6M71) |
- |
10ns |
pkCSM Mi |
SP : Maslinic acid (-9.3), Glycyrrhizic acid (-9.3), Corosolic acid (-9.4) ACE2 : Glycyrrhizic acid (-9.5), Maslinic acid (-8.5), Obacunone (-8.1) |
- |
ACE2 : Arg273, His345, Arg393 |
(29) |
MolDoc, SAP, ADMET. |
Cresset Flare Docking, LigPlus, pkCSM |
37 phytoconstituents from K. Kudineer Chooranam and JACOM |
Spike Protein (6VSB) |
(based on trial and error) |
- |
pkCSM |
Chrysoeriol (-11.39), Luteolin (-11.15), Quercetin (-11.47) |
- |
SP : Cys336, Phe338, Gly339, Phe342, Asn343, Thr345, Asp364, Val367, |
(30) |
BSP, MolDoc, MD |
CASTp, Rampage, PyRx 0.8, GROMACS 2020, LigPlot+, VMD |
10 dietary flavonoid compounds |
Spike Protein (6M0J) |
44.34 x 70.98 x 44.58 |
1ns 300K |
- |
Naringin (-9.8) |
Dexa-methasone |
*SP : Asp367, Thr371, Glu406, Ser409, Lys441 |
(31) |
MolDoc, MD |
UCSF Chimera, Autodock Vina, GROMACS 5.1 |
24 drug molecules |
ACE2 (6M0J) |
- |
10ns 300K |
- |
Cefpiramide (-9.1) |
- |
- |
(32) |
VS, MolDoc, FE |
MOE, AD, PT2 |
500,000+ small molecules from Chembridge Corp. |
ACE2 (1R42) |
- |
- |
PT2 |
Chem7781334 (-5.87), Chem7676800 (-5.84), Chem7956590 (-5.83) |
- |
ACE2 : Gln24, Asp30, His34, Tyr41, Gln42, Met82, Lys353, Arg357 |
(33) |
MolDoc, PK, MD |
DSV, AD4.2, Mi, admetSAR, GROMACS 5.1, |
57 phyto-ligands from Indian Herbs |
ACE2 (1R42), Spike Protein (6VYB) |
ACE2 : 22.5 x 22.5 x 22.5 SP : 30 x 28.125 x 25.5 |
25ns 300K |
Mi, admetSAR |
ACE2: Apigenin-7-O-glucuronide (-8.8), Ellagic acid (-8.4),
Vasicolinone (-7,5), SP: Apigenin-7-O-glucuronide (-7.2), Ellagic acid (-6.2), Vasicolinone
(-6,4) |
- |
ACE2 : Lys26, Gln89 SP: Tyr28, Tyr269, Asp290 |
(34) |
MolDoc, ADMET, MD, PCA, FE |
ADT ADV, SA, pkCSM, GROMACS 5.1 |
1000 plant bioactive terpenes compound |
Spike Protein (6LZG) |
45 x 45 x 45 |
50ns 300K |
SA, pkCSM |
NPACT01552 (-11.0), NPACT01557 (-10.3), NPACT00631 (-9.5) |
- |
Tyr449, Tyr453, Glu484, Gly496, Gln498, Asn501 |
(35) |
Act.Site, MolDoc, ADMET. |
DSV, UCSF Chimera, ADT CASTp, PyRx, ADV, SA, AdmetSAR, GraphPad Prism |
791 FDA-approved drugs |
ACE2 (6LZG), 3CLpro (6LU7), ADP ribose phosphatase of NSP3 (6VXS), NSP9 RNA binding protein (6W4B) |
(residues on active site included) |
- |
SA, AdmetSAR |
Ethynodiol diacetate (-15.6), Methylnaltrexone (-15.5), Ketazolam (-14.5), Naloxone (-13.6), |
Lopinavir, Remdesivir, Hydroxy-chloroquine |
Ile291 |
(36) |
MolDoc, MD |
Protein Prep Wizard, Schrodinger's HTVS, Glide SP, Schrodinger Desmond platform |
2800 FDA-approved drugs |
ACE2 (1R4L) TMPRSS2 (Hom. Mod.) |
(Glide grid tool) |
50ns 300K |
- |
Valrubicin (-8.59), Lopinavir (-7.89), Fleroxacin (-7.73), Alvimopan (-8.51), Arbekacin (-7.74), Dequalinium (-7.73) |
- |
Arg273, Lys363, Asp367, Thr371, |
(37) |
VS Pharmacophore MolDoc, ADMET, MD, FE |
LigandScout 4.3, DSV 16.1, PyRx, AD4, ADV, SA |
11,295 compounds from the database |
ACE2 (1R4L) |
20.05 x 17.92 x 8.75 |
250ns 300K |
SA |
Amb17613565 (-7.5), |
XX5 |
Asn149, Gly268, Asp269, Arg273, Asn277, Asp350, Lys363, Thr365, Asp367, Arg393 |
(38) |
MolDoc |
ADV, M2M |
28 natural plants from TCM |
ACE2 (7DF4), Spike Protein (7DF4) |
(Interacting critical residues in Spike Protein and ACE2 complex) |
- |
- |
ACE2: Oleanolic acid (-7.1), Tryptanthrin (-6.55), Chrysophanol (-6.16), Rhein (-4.69) SP: Oleanolic acid (-3.74), Tryptanthrin (-4.26), Chrysophanol (-4.07), Rhein (-3.66) |
- |
ACE2: His34, Lys94, Gln102, Lys562, Trp566 SP: Arg403, Tyr449, Tyr453, Gln493, Ser494, Tyr495, Gly496 |
(39) |
ADMET, MolDoc, Qua.Calc, MD, |
SA, admetSAR, UCSF Chimera, AD4.2, DSV Gaussian16 suite, GROMACS 2015, |
586 phytochemicals from 47 medicinal plants |
ACE2 (6M0J), Spike Protein (6LZG), Plpro (6W9C), Mpro (6LU7), Importin α-5 (2JDQ), Importin β-1 (1F59) |
33.75 x 33.75 x 33.75 |
50ns 300K |
SA, AdmetSAR |
ACE2: Hetisinone (-8.46) SP: |
Arbidol (SP), Hydroxychloroquine (ACE2) |
ACE2: Ala348, Trp349, His378, His401 SP: Arg23, Ser182, Phe183, Leu185 |
(40) |
MolDoc, FE, MD. |
Schrodinger Drug Discovery Suite, Pymol 2.4.1 |
85 antiviral and antimicrobial flavonoid compounds |
ACE2 (6M0J), Spike Protein (6M0J), Mpro (6LU7), NSP12 (7BV2), NSP15 (6WXC) |
30 x 30 x 30 |
100ns 300K |
- |
SP: Isosilybin (-5.19) ACE2: Legalon (-2.78) |
- |
SP: Tyr453, Gly496, Gln498, Tyr505 ACE2: Lys26, Glu37, Asn90, Gln96, Ala387, Arg393 |
(41) |
VS, MolDoc, ADMET |
Chimera 1.13, Molegro Virtual Docker v6.0, PyRx 0.8, DSV, ADV, ADT1.5.6, OpenBabel SA, ADMETlab 2.0 |
100,000+ chemical compounds from ChemDiv |
Spike Protein (6M0J), Mpro (7AMJ), RdRp (7B3D), Plpro (6WX4) |
23.60 x 45.00 x 21.88 |
- |
SwissADME, ADMETlab 2.0 |
8008-2051 (-9.0) K279-0710 (-8.8) |
Nebivolol |
Arg403, Tyr449, Tyr453, Ser494, Gly496, Gln498, Asn501, |
3.4 Molecular Docking
The docking method is another option for virtual screening. It
can also further be used to validate virtual screening results. Molecular
docking studies are mainly used to predict the ligand-receptor complex's
binding affinity, preferred binding pose, and interaction with the least amount
of free energy. Docking studies also can reveal the interaction
between protein-ligand, protein-nucleotide, and also protein-protein
interactions (PPIs). Noncovalent interactions can include ionic bonds, hydrogen
bonds, and van der Waals interactions (60). In addition to the
software mentioned previously in the summary of studies, several other software
options are widely used in many molecular docking studies. RosettaLigand (61), Surflex (62), and Ligandfit (63) are some of the other
popular software.
The docking mechanism is a two-step mechanism. It started
with sampling conformation of the ligand in the receptor then followed by
ranking these conformations using a scoring function. The effectiveness of a
docking programme is determined by two major factors: search algorithms and
scoring functions (64).
There are 2 main algorithms in molecular docking, which is
the stochastic algorithm when where the search is carried out by modifying the
ligand conformation or population of ligands. Example algorithms for this
method are Monte Carlo and Genetic Algorithms (65). On the other hand, systematic
search methods promote minor modifications in structural parameters, which
gradually change the conformation of the ligands. The algorithm examines the
energy landscape of the conformational space and, after many search and
evaluation cycles, converges on the lowest energy solution corresponding to the
most likely binding mode. The systematic algorithms are presented in GLIDE
and DOCK (66).
Scoring functions are used to predict the target-ligand
complex's binding free energy, which is a measure of the small molecule's
binding potency for the biomolecular target. Scoring functions are classified
into three types: force-field-based scoring, empirical-based scoring, and
knowledge-based scoring (67). AutoDock scoring is an
example of force-field-based scoring, which is derived from the classic force
field and evaluates the binding energy as a sum of nonbonded interactions.
Empirical-based scoring, such as GlideScore, is a weighted sum of various types
of receptor-ligand interactions. DrugScore is a knowledge-based scoring system
that penalises repulsive interactions while favouring preferred contact between
each of the atoms in the protein and ligand within a given cut-off (64).
3.5 Grid Size and
Parameter
In our reviewed studies, we examined several variations in
the grid size parameter. Several studies reported the grid size qualitatively,
stating that they used active site residues or critical interacting residues as
grid size (22,24,35,38). Because of the lack of
quantitative data, this approach of disclosures would, of course, reduce the
reproducibility of the studies. In other studies, the grid size is determined
differently for each receptor target (33). In others, it is the
same size for all tested receptors (23,25–27,39–41). Understandably, a
specific PDB will have a set of specific grid sizes that can be used in it, but
the grid size should always be bigger than the ligand that is docked. According
to Feinstein and Brylinski's research, the highest accuracy is obtained when
the dimensions of the search space are 2.9 times larger than the radius of the gyration
of a docking compound (68). They developed a
procedure based on this discovery to customise the box size for individual
query ligands to maximise docking accuracy. This finding essentially reduces
the number of scoring failures caused by overly generous box sizes while also
avoiding sampling failures caused by a too-narrow search space.
3.6 Database of Chemicals
Although the majority of the chemical structure is obtained
from PubChem, the dataset used for each study is unique to each author. Several
studies are being conducted to investigate whether already approved drugs can
be repurposed from their original purpose to become ACE2 blockers and
SARS-CoV-2 inhibitors (31,35,36). Another method for
preparing the dataset for testing is to look for compounds found in traditional
medicine or plant constituents as drug candidates (22,24,39,40,25,27–30,33,34,38). The final notable
approach is to select a chemical suitable as a candidate from a large dataset
ranging from 10,000 to 500,000 compounds (32,37,41). However, these
differences in approach may provide beneficial insight from different
perspectives, bringing us closer to real drug candidates ready for development.
3.7 Target Receptors
We may find a range of PDB IDs for ACE2 and SARS-CoV-2 Spike Protein receptors in this review study. The same PDB ID was used in several articles for the same receptors. We can see this in four publications (24,25,32,33) for ACE2, which used PDB 1R42 (69) as the receptors. Some other interesting point is that a PDB file can be used as a receptor target for ACE2 or SARS-CoV-2 because it contains both receptors in one file. We can see the PDB 6M0J (70) can be used as a SARS-CoV-2 Spike Protein target in 5 articles